Key Highlights

  • Zura Bio (NASDAQ:ZURA) ended Tuesday, November 10, 2026 at USD 1.48, a 19.31% gain from a calculated prior close of USD 1.24, a recovery after a plunge of roughly 76% reported in the previous session.
  • The Phase 2 TibuSHIELD study of tibulizumab, run in 247 patients, did not reach its primary endpoint: lesion counts dropped 56% and 58.1% on the two doses compared with 52.5% on placebo at 16 weeks.
  • Trading totalled 6.71M shares, a relative Volume of 0.71, valued near USD 9.93 million at the closing price (calculated), set against a Market Value of USD 142.5 million.
  • The company disclosed cash and equivalents of USD 187.7 million at September 30, 2026, funding that extends through at least the end of 2028, along with trailing diluted EPS of USD -1.25.

What Lifted Zura Bio on November 10 (+19.31%)

The clinical-stage immunology company closed the regular session at USD 1.48, a 19.31% gain. Basic arithmetic gives a calculated prior close near USD 1.24 for Monday, November 9, 2026. Published coverage reported that the shares sank roughly 76% on the study news, touching USD 0.97 and an intraday record low of USD 0.93,, with about 81% lost year to date. The USD 1.48 close stands about 53% over the USD 0.97 mark (calculated). Volume of 6.71M shares at a relative volume of 0.71 shows turnover roughly 29% under the recent average.

The Rationale: A Bounce After the TibuSHIELD Study Miss

The key event is the Phase 2 TibuSHIELD readout for tibulizumab, also known as ZB-106, in hidradenitis suppurativa. The 16-week study enrolled 247 patients. Lesion counts declined 56% and 58.1% across the two dose arms versus 52.5% with placebo, and both the primary and key secondary endpoints were missed. Guggenheim lowered its price target to USD 8, and a law firm announced an investigation on behalf of investors. No separate announcement dated November 10, 2026 surfaced. In general terms, once a stock collapses in one day and trades beneath the cash on its balance sheet, bargain hunting and short covering can follow, but these are broad mechanisms and not confirmed causes.

Valuation, Liquidity and Risks for Zura Bio

The USD 142.5 million market value falls short of reported cash of USD 187.7 million, a difference of about USD 45.2 million (calculated). That works out to roughly 96.3 million shares at USD 1.48 (calculated). No P/E applies because trailing diluted EPS is USD -1.25, and EPS growth is -76.37%. The Dividend Yield is 0.00%. Cash is not money holders can simply claim, since the company has to pay for operations, and a lower share price can trigger a Nasdaq minimum bid deficiency notice under USD 1.00. Upcoming readouts include systemic sclerosis results expected in the first half of 2027 and polymyalgia rheumatica data in the fourth quarter of 2028. Turnover near USD 9.93 million is meaningful. Nothing here suggests the advance will persist.

Where Things Stand

Zura Bio (NASDAQ:ZURA) bounced 19.31% to USD 1.48 on November 10, 2026, the session after a plunge of about 76% on a failed Phase 2 tibulizumab study, and no new company news was identified. The gain came on 6.71M shares, a relative volume of 0.71, from a calculated prior close of USD 1.24. Cash of USD 187.7 million is greater than the USD 142.5 million market value, yet trailing EPS is USD -1.25 and the pipeline now leans on later-stage readouts.